$CNMD|4Feb 3, 11:38 AM ET

CONMED CORP 4

4 · CONMED CORP · Filed Feb 3, 2015

Form 4

Period: 2015-02-02

President Conmed Linvatec

Transactions

Exercise/Conversion
Common Stock
2015-02-02$26.09/sh+4,000$104,360→ 19,122 total
Tax Payment
Common Stock
2015-02-02$47.85/sh−2,722$130,248→ 16,400 total
Exercise/Conversion
Sars (Stock Appreciation Rights)
2015-02-02−4,000→ 6,000 total
Exercise: $26.09Exp: 2022-06-01→ Common Stock (4,000 underlying)
Tax Payment
Common Stock
2015-02-02$47.85/sh−6,893$329,830→ 15,122 total
Exercise/Conversion
Common Stock
2015-02-02$26.69/sh+10,000$266,900→ 22,015 total
Exercise/Conversion
Common Stock
2015-02-02$32.93/sh+2,000$65,860→ 18,400 total
Tax Payment
Common Stock
2015-02-02$47.85/sh−1,563$74,790→ 16,837 total
Exercise/Conversion
Sars (Stock Appreciation Rights)
2015-02-02−10,000→ 0 total
Exercise: $26.69Exp: 2018-06-01→ Common Stock (10,000 underlying)
Exercise/Conversion
Sars (Stock Appreciation Rights)
2015-02-02−2,000→ 8,000 total
Exercise: $32.93Exp: 2023-06-01→ Common Stock (2,000 underlying)

Footnotes (2)

[F1]The stock appreciation rights ("SARs") were granted under the Company's 2006 Stock Incentive Plan and generally vest in equal amounts over a five year period.
[F2]The stock appreciation rights ("SARs") were granted under the Company's 1999 Amended and Restated Long-Term Incentive Plan and generally vest in equal amounts over a five year period.

Documents

1 file